Roche's Fenebrutinib Achieves Breakthrough Results in Multiple Sclerosis Trials
TL;DR Summary
The website www.roche.com has restricted access for certain IP addresses using Cloudflare, resulting in an error message (Error 1005) that blocks access based on the user's autonomous system number (ASN).
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progress... Roche
- Roche's experimental MS drug hits main goal in one of two key trials Reuters
- Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials The Wall Street Journal
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s GlobeNewswire
- Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosis Endpoints News
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
56%
68 → 30 words
Want the full story? Read the original article
Read on Roche